Literature DB >> 31702585

Conformational heterogeneity in apo and drug-bound structures of Toxoplasma gondii prolyl-tRNA synthetase.

Siddhartha Mishra1, Nipun Malhotra1, Shreya Kumari1, Mizuki Sato2, Haruhisa Kikuchi2, Manickam Yogavel1, Amit Sharma1.   

Abstract

Prolyl-tRNA synthetase (PRS) is a member of the aminoacyl-tRNA synthetase family that drives protein translation in cells. The apicomplexan PRSs are validated targets of febrifugine (FF) and its halogenated derivative halofuginone (HF). PRSs are of great interest for drug development against Plasmodium falciparum and Toxoplasma gondii. In this study, structures of apo and FF-bound T. gondii (TgPRS) are revealed and the dynamic nature of the conformational changes that occur upon FF binding is unraveled. In addition, this study highlights significant conformational plasticity within two different crystal structures of apo PRSs but not within drug-bound PRSs. The apo PRSs exist in multi-conformational states and manifest pseudo-dimeric structures. In contrast, when FF is bound the PRS dimer adopts a highly symmetrical architecture. It is shown that TgPRS does not display extant fold switching, in contrast to P. falciparum PRS, despite having over 65% sequence identity. Finally, structure-comparison analyses suggest the utility of r.m.s.d. per residue (r.m.s.d./res) as a robust tool to detect structural alterations even when the r.m.s.d. is low. Apo TgPRS reveals FF/HF-induced rigidity and this work has implications for drug-design studies that rely on the apo structures of target proteins.

Entities:  

Keywords:  apo–holo transistions; comparative crystallography; drug design; enzyme–inhibitor complexes; prolyl-tRNA synthetase; r.m.s.d. per residue profile; toxoplasmosis

Mesh:

Substances:

Year:  2019        PMID: 31702585     DOI: 10.1107/S2053230X19014808

Source DB:  PubMed          Journal:  Acta Crystallogr F Struct Biol Commun        ISSN: 2053-230X            Impact factor:   1.056


  2 in total

1.  Drug targeting of aminoacyl-tRNA synthetases in Anopheles species and Aedes aegypti that cause malaria and dengue.

Authors:  Soumyananda Chakraborti; Jyoti Chhibber-Goel; Amit Sharma
Journal:  Parasit Vectors       Date:  2021-12-11       Impact factor: 3.876

2.  Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development.

Authors:  Yogavel Manickam; Nipun Malhotra; Siddhartha Mishra; Palak Babbar; Abhishek Dusane; Benoît Laleu; Valeria Bellini; Mohamed-Ali Hakimi; Alexandre Bougdour; Amit Sharma
Journal:  PLoS Pathog       Date:  2022-03-25       Impact factor: 6.823

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.